Development of VIP agonists and antagonists with tissue and receptor specificity: Effects on behavioral maturation, sexual function, and the biologic clock

Annals of the New York Academy of Sciences

Volumn 805, Issue , 1996, Pages 159-169

  Gozes, I ^a   Lilling, G ^a   Davidson, A ^a   Bardea, A ^a   Reshef, A ^a   Glazer, R ^a   Zamostiano, R ^a   Ashur Fabian, O ^a   Ticher, A ^a   Ashkenazi, I E ^a   Moody, T W ^b   Rubinraut, S ^c   Fridpon, M ^c   Brenneman, D E ^d  

^a TEL AVIV UNIVERSITY   (Israel)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR STIMULATING AGENT; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; NEUROPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

BEHAVIOR; BIOLOGICAL RHYTHM; CHEMICAL MODIFICATION; CONFERENCE PAPER; DRUG DESIGN; HORMONE RECEPTOR INTERACTION; HORMONE STRUCTURE; IMPOTENCE; NONHUMAN; RECEPTOR AFFINITY; SEXUAL FUNCTION; STRUCTURE ACTIVITY RELATION; TISSUE SPECIFICITY;

EID: 0030477739     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb17481.x     Document Type: Conference Paper

References (60)

1. GOZES, I., S. K. MCCUNE, L. JACOBSON, D. WARREN, T. W. MOODY, M. FRIDKIN & D. E. BRENNEMAN. 1991. An antagonist to vasoactive intestinal peptide: Effects on cellular functions in the central nervous system. J. Pharmacol. Exp. Ther. 257: 959-966.
2. GOZES, I., G. LILLING, R. GLAZER, A. TICKER, I. E. ASHKENAZI, A. DAVIDSON, S. RUBINRAUT, M. FRIDKIN & D. E. BRENNEMAN. 1995. Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J. Pharmacol. Exp. Ther. 273: 161-167.
3. HARMAR, T. & E. LUTZ. 1994. Multiple receptors for PACAP and VIP. TIPS 16: 97-99.
4. MAGISTRETTI, P. J. & M. SCHORDERET. 1984. VIP and noradrenaline act synergistically to increase cyclic AMP in cerebral cortex. Nature 308: 280-282.
5. FATATIS, A., L. A. HOLTZCLAW, R. AVIDOR, D. E. BRENNEMAN & J. T. RUSSELL. 1994. Vasoactive intestinal peptide increases intracellular calcium in astroglia: Synergism with alpha-adrenergic receptors. Proc. Natl. Acad. Sci. U.S.A. 91: 2036-2040.
6. BRENNEMAN, D. E. & L. E. EIDEN. 1986. Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc. Natl. Acad Sci. U.S.A. 83: 1159-1162.
7. GOZES, I. & D. E. BRENNEMAN. 1989. VIP molecular biology and neurobiological function. Mol. Neurobiol. 3: 201-236.
8. GOZES, I., A. RESHEF, D. SALAH, S. RUBINROUT & M. FRIDKIN. 1994. Stearyl-norleucine-VIP: A novel VIP analogue for non-invasive impotence treatment. Endocrinology 134: 2121-2125.
9. GOZES, Y., D. E. BRENNEMAN, M. FRIDKIN, R. ASOFSKY & I. GOZES. 1991. A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes. Brain Res. 540: 319-321.
10. MOODY, T. W., F. ZIA, A. L. GOLDSTEIN, P. H. NAYLOR, E. SARIN, D. E. BRENNEMAN, A. M. C. KOROS, J. C. REUBI, L. Y. KORMAN, M. FRIDKIN & I. GOZES. 1992. VIP analogues inhibit small cell lung cancer growth. Biomed. Res. 13(Suppl. 2): 131-135.
11. MOODY, T. W., F. ZIA, M. DRAOUI, D. E. BRENNEMAN, M. FRIDKIN, A. DAVIDSON & I. GOZES. 1993. A novel VIP antagonist inhibits non-small cell lung cancer growth. Proc. Natl. Acad. Sci. U.S.A. 90: 4345-4349.
12. ZIA, H., T. HIDA, S. JAKOWLEW, M. BIRRER, Y. GOZES, J. C. REUBI, M. FRIDKIN, I. GOZES & T. W. MOODY. 1996. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Res. 56: 3486-3489.
13. WOLLMAN, Y., G. LILLING, M. N. GOLDSTEIN, M. FRIDKLN & I. GOZES. 1993. Vasoactive intestinal peptide: A growth promoter in neuroblastoma cells. Brain Res. 624: 339-341.
14. LILLING, G., Y. WOLLMAN, M. N. GOLDSTEIN, S. RUBINRAUT, M. FRIDKIN, D. E. BRENNEMAN & I. GOZES. 1995. Inhibition of human neuroblastoma growth by a specific VIP antagonist. J. Mol. Neurosci. 5: 231-239.
15. GOZES, I., D. E. BRENNEMAN, G. LILLING, A. DAVIDSON & T. W. MOODY. 1994. Neuropeptide Regulation of Mitosis. Ann. N.Y. Acad. Sci. 739: 253-261.
16. GRESSENS, P., J. M. HILL, B. PAINDAVEINE, I. GOZES, M. FRIDKIN & D. E. BRENNEMAN. 1994. Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. J. Clin. Invest. 94: 2020-2027.
17. GRESSENS, P., J. M. HILL, I. GOZES, M. FRIDKIN & D. E. BRENNEMAN. 1993. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature 362: 155-158.
18. GOZES, I. & M. FRIDKIN. 1992. A fatty neuropeptide: Potential drug for non-invasive impotence treatment in a rat model. J. Clin. Invest. 90: 810-814.
19. GOZES, I. & M. FRIDKIN. 1993. Lipophilic vasoactive intestinal peptide: Potential drug for non-invasive impotence treatment. In Peptide Chemistry 1992, N. Yanaihara, Ed.: 442-445 ESCOM. Leiden, The Netherlands.
20. THERAULT, Y., Y. BOULANGER & S. ST.-PIERRE. 1991. Structural determination of the vasoactive intestinal peptide by two dimensional H-NMR spectroscopy. Biopolymers 31: 459-464.
21. LEROUX, F., J. F. GOOSENS, N. POMMERY & J. P. HENICHART. 1994. A new vasoactive intestinal peptide antagonist discriminates VIP receptors on guinea pig trachea and human neuroblastoma cells. Regul. Pept. 52: 119-128.
22. BOLIN, D. R., J. MICHALEWSKY, M. A. WASSERMAN & M. O'DONELL. 1995. Design and development of a vasoactive intestinal peptides analog as a novel therapeutic for bronchial asthma. Biopolymers 37: 57-66.
23. GOZES, I., E. MELTZER, S. RUBINRAUT, D. E. BRENNEMAN & M. FRIDKIN. 1989. Vasoactive intestinal peptide potentiate sexual behavior: Inhibition by novel antagonist. Endocrinology 125: 2945-2949.
24. 2 as a VIP antagonist. Endocrinology 116: 2643-2649.
25. 17)VIP. Am. J. Physiol. 250: G553-G557.
26. SINGH, P. 1988. A synthetic peptide, L-8-K, and its antibody both inhibit specific binding of vasoactive intestinal peptide to hamster pancreatic cancer cells. Ann. N.Y. Acad. Sci. 527: 679-681.
27. BISSONNETTE, B. M., M. J. COLLEN, H. ADACHI, R. T. JENSEN & J. D. GARDNER. 1984. Receptors for vasoactive intestinal peptide and secretin on rat pancreatic acini. Am. J. Physiol. 246: G710-G717.
28. VENUGOPALAN, C. S., E. HOLMES & S. R. PILLAI. 1989. Blockade of NANC inhibitory tracheal response by peptide T. Fed. Am. Soc. Exp. Biol. J. 3: A287.
29. SVOBODA, M., M. TASTENOY, J. VAN RAMPELBERGH, J. F. GOOSSENS, P. DE NEEF, M. WAELBROECK & P. ROBBERECHT. 1994. Molecular cloning and functional characterization of a human VIP receptor from SUB-T1 lymphoblasts. Biochem. Biophys. Res. Commun. 205: 1617-1624.
30. USDIN, T. B., T. I. BONNER & E. MEZEY. 1994. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135: 2662-2680.
31. ARIMURA, A., A. SOMOGYVARI-VIGH, C. WEILL, R. C. FIORE, I. TATSUNO, V. BAY & D. E. BRENNEMAN. 1994. PACAP functions as a neurotrophic factor. Ann. N.Y. Acad. Sci. 739: 228-243.
32. SONE, M., D. M. SMITH, M. A. GHATEI, I. GOZES, D. E. BRENNEMAN, M. FRIDKIN & S. R. BLOOM. 1994. Pituitary adenylate cyclase activating polypeptide (PACAP)/vasoactive intestinal peptide (VIP) receptor subtypes in rat tissues: Investigation of receptor binding and molecular identification by chemical cross linking. Biomed. Res. 15: 145-153.
33. ROBBERECHT, P., M. WAELBROCK, P. DE NEEF, P. TASTENOY, P. GOURLET, J. COGNIAUX & J. CHRISTOPHE. 1988. A new type of functional VIP receptor has an affinity for helodermin in human SUB-T1 lymphoblasts. FEES Lett. 228: 351-355.
34. SHIVERS, B. D., T. J. GORCS, P. E. GOTTSCHALL & A. ARIMURA. 1991. Two high affinity binding sites for pituitary adenylate cyclase activating polypeptide have different tissue distributions. Endocrinology 128: 3055-3065.
35. LAM, H. C., K. TAKAHASHI, M. A. GHATEI, S. M. KANSE, J. M. POLAK & S. R. BLOOM. 1990. Binding sites of a novel neuropeptide pituitary adenylate cyclase activating polypeptide in the rat brain and lung. Eur. J. Biochem. 193: 725-729.
36. DELPORTE, C., P. POLOCZEK, P. DE NEEF, P. VERTONGEN, E. CICCARELLI, M. SVOBODA & A. HERSCHELZ. 1995. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide stimulate two signaling pathways in CHO cells stably transfected with the selective type IPACAP receptor. Mol. Cell. Endocrinol. 107: 71-76.
37. SPENGLER, D., C. WAEBER, C. PNATALONI, F. HOLSBOER, J. BOCKAERT, P. H. SEEBURG, & L. JOURNOT. 1993. Differential signal transduction by five splice variants of PACAP receptor. Nature 365: 170-175.
38. BURLEIGH, D. E. & S. KIRKHAM. 1993. Lack of effect of three putative vasoactive intestinal peptide-induced secretory responses in rat colon. Eur. J. Pharmacol. 249: 239-242.
39. FISHBEIN, V. A., D. H. COY, S. J. HOCART, N.-Y. JIANG, J. E. MROZINSKI, JR., S. A. MANTEY & R. T. JENSEN. 1994. A chimeric VIP-PACAP analogue but not VIP pseudopeptides functions as VIP receptor agonists. Peptides 15: 95-100.
40. GLOWA, J. R., L. V. PANLILIO, D. E. BRENNEMAN, I. GOZES, M. FRIDKIN & J. M. HILL. 1992. Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Res. 570: 49-53.
41. HILL, J. M., R. F. MERVIS, J. POLITI, S. K. MCCUNE, I. GOZES, M. FRIDKIN & D. E. BRENNEMAN. 1994. Blockade of VIP during neonatal development induces neuronal damage and increases VIP and VIP receptors in brain. Ann. N.Y. Acad. Sci. 739: 211-225.
42. HILL, J. M., I. GOZES, J. L. HILL, M. FRIDKIN & D. E. BRENNEMAN. 1991. Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. Peptides 12: 187-192.
43. GOZES, I., A. DAVIDSON, M. DRAOUI & T. W. MOODY. 1992. The VIP gene is expressed in non-small cell lung cancer cell lines. Biomed. Res. 13(Suppl. 2): 37-39.
44. BRENNEMAN, D. E., J. M. HILL, G. W. GLAZNER, I. GOZES & T. W. PHILIPS. 1995. Interleukin-1 alpha and vasoactive intestinal peptide: Enigmatic regulation of neuronal survival. Int. J. Devl. Neurosci. 13: 187-200.
45. SAID, S. I., ED. 1982. Vasoactive Intestinal Peptide. In Advances in Peptide Hormone Research Series: 1-512. Raven Press. New York.
46. FAUCHERE, J. L., M. CHATEON, L. B. KIER, A. VERLOOP & V. PLISKA. 1988. Amino acid side parameters for correlation studies in biology and pharmacology. Int. J. Pept. Protein Res. 32: 269-278.
47. 17-VIP: A Non-invasive Impotence Drug and a Potent Agent of Neuro-Protection. Drugs Future. 20: 680-685.
48. GOZES, I., M. FRIDKIN, H. WESTPHAL, J. GLOWA, J. M. HILL, A. RESHEF, S. ZHUKOVSKY, T. WANER, A. NISKA, S. RUBLNROUT, G. LILLLNG, A. DAVIDSON, R. GLAZER-STEINER, T. W. MOODY, W. ROSTENE & D. E. BRENNEMAN. 1994. Neuronal VIP: From gene to sexual behavior, memory and clinical applications. Proc. Int. Symp. on VIP, PACAP and Related Regulatory Peptides. 314-324. World Scientific Publishing Co. Strasbourg, France.
49. OLAH, Z., C. LEHEL, W. B. ANDERSON, D. E. BRENNEMAN & D. V. AGOSTON. 1994. Subnanomolar concentrations of VIP induces the nuclear translocation of protein kinase C in neonatal rat cortical astrocytes. J. Neurosci. Res. 39: 355-363.
50. FOUCHIER, F., J. PICHON & P. FORGET. 1994. Inhibition of vasoactive intestinal peptide (VIP) binding on human melanoma cells IGR39 by nitric oxide: cGMP is not involved. Eur. J. Cell. Biol. 64: 71-77.
51. CARD, J. P., S. FITZPATRICK-MCELLIGOTT, I. GOZES & F. BALDING, JR. 1988. Localization of vasopressin, somatostatin and VIP messenger RNA in the rat suprachiasmatic nucleus. Cell Tissue Res. 252: 307-315.
52. DUSSAILLANT, M., A. SARRIEAU, I. GOZES, A. BEROD & W. ROSTENE. 1992. Quantitative and qualitative distribution of cells expressing VIP/PHI precursor mRNA in the rat brain. Neuroscience 50: 519-530.
53. GOZES, I., J. GLOWA, D. E. BRENNEMAN, S. K. MCCUNE, E. LEE & H. WESTPHAL. 1993. Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene. J. Mol. Neurosci. 4: 185-193.
54. GOZES, I., Y. SHANI, B. LIU & J. P. BURBACH. 1989. Diurnal variation in vasoactive intestinal peptide messenger RNA in the suprachiasmatic nucleus of the rat. Neurosci. Res. Commun. 5: 83-86.
55. ALBERTS, H. E., E. G. STOPA, R. T. ZOELLER, J. S. KAUER, J. C. KING, J. S. FINK, H. MOBTAKER & H. WOLFE. 1990. Day-night variation in prepro VIP/PHI mRNA within the suprachiasmatic nucleus. Mol. Brain Res. 7: 85-89.
56. GLAZER, R. & I. GOZES. 1994. Diurnal oscillation in vasoactive intestinal peptide gene expression independent of environmental light entraining. Brain Res. 644: 164-168.
57. HARNEY, J. P., K. SCARBOROUGH, K. ROSEWELL & P. M. WISE. 1993. Effect of intracerebral infusion of VIP antisense oligonucleotides into the suprachiasmatic nuclei (SCN) on the LH surge in the rat. Neurosci. Soc. Abs. 19: 573.
58. PROSSER, R. A. & M. U. GILLETE. 1991. Cyclic changes in cAMP concentration and phosphodiesterase activity in a mammalian circadian clock studied in vitro. Brain Res. 568: 185-192.
59. FISHBEIN, V. A., D. H. COY, S. J. HOCART, N.-Y. JIANG, J. E. MROZINSKI, JR., S. A. MANTEY & R. T. JENSEN. 1994. A chimeric VIP-PACAP analogue but not VIP pseudopeptides functions as VIP receptor agonists. Peptides 15: 95-100.
60. PRESTI, M. E. & J. D. GARDNER. 1993. Receptor antagonists for gastrointestinal peptides. Am. J. Physiol. 264: G399-G406.